Pressure BioSciences, Inc. Upgraded by EdgeWater Research Partners LLC.WEST BRIDGEWATER, Mass. -- Pressure BioSciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : PBIO PBIO Processor Backplane I/O (NASA) PBIO Portable Binary Input Output ) today announced that in an update to an initial research report on the Company, EdgeWater Research Partners LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control ("EdgeWater") has upgraded PBI's rating from a 4 to a 6 and re-established a 12-18 month price target. Of the 20 companies currently covered by EdgeWater, only one has a rating greater than 6. Copies of the updated and initial research reports on PBI PBI protein-bound iodine. PBI abbr. protein-bound iodine PBI, n See iodine, protein-bound. PBI protein-bound iodine. can be obtained free of charge by contacting Mr. David Lavigne at EdgeWater (www.edgewaterresearch.com or 303-593-2877). Analyst Coverage Disclaimer Pressure BioSciences is announcing the availability of EdgeWater's updated research report solely for convenience. Any opinions, estimates, or forecasts regarding Pressure BioSciences' historical or predicted performance or operations, including predictions of stock price, made by EdgeWater are theirs alone and do not represent opinions, judgments, estimates, or forecasts of Pressure BioSciences or its management. Pressure BioSciences does not endorse, adopt, or concur with information, conclusions, or recommendations in either EdgeWater's initial or updated research reports on the Company. Pressure BioSciences subscribes for EdgeWater's newsletter and research information, and has purchased EdgeWater's research reports. For the past two years, Pressure BioSciences has paid a fee of $8000 to attend and present at EdgeWater's fall Micro/Small Cap Conference for Investment Professionals. About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT (Private Communications Technology) A protocol from Microsoft that provides secure transactions over the Web. See security protocol. ). PCT uses cycles of hydrostatic pressure hydrostatic pressure The pressure exerted by a fluid at equilibrium at a given point within the fluid, due to the force of gravity. Hydrostatic pressure increases in proportion to depth measured from the surface because of the increasing weight of fluid between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation inactivation /in·ac·ti·va·tion/ (in-ak?ti-va´shun) the destruction of biological activity, as of a virus, by the action of heat or other agent. , the control of enzymes, immunodiagnostics, and protein purification Protein purification is a series of processes intended to isolate a single type of protein from a complex mixture. Protein purification is vital for the characterisation of the function, structure and interactions of the protein of interest. . Forward Looking Statements Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006; in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005; and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Visit us at our website http://www.pressurebiosciences.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion